Cancer drug repurposed for Alzheimer's shows early promise in small trial
NCT ID NCT02947893
First seen Feb 14, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study tested a low dose of nilotinib, a drug normally used for leukemia, in 37 people with mild-to-moderate Alzheimer's. The goal was to see if the drug is safe and whether it can reach the brain and affect proteins linked to Alzheimer's. Participants took the drug or a placebo daily for 6 months, and researchers monitored side effects and measured changes in spinal fluid and brain scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20057, United States
Conditions
Explore the condition pages connected to this study.